ATOSSA THERAPEUTICS, INC. (ATOS)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$15.3M
Cash & Equivalents
$9.6M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$24M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-11-01 Phase2 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05607004 (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer PHASE2 Active Not Recruiting 87

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for ATOS.

SEC EDGAR Filings

All SEC filings for ATOSSA THERAPEUTICS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.